massive-demand-for-sinopharm-bodes-well-for-ipo-pipeline

Massive demand for Sinopharm bodes well for IPO pipeline

The Chinese pharmaceutical distributor prices at the top to raise $1.13 billion after attracting $110 billion worth of orders. Separately, Digital China raises $49 million from a top-up placement.

Sinopharm, the largest distributor of pharmaceutical products in China and the first company to price a Hong Kong initial public offering in the current flood of IPOs, received massive demand from both institutions and retail investors, according to sources.

The response, which was described as crazy by some bankers working on the deal, allowed Sinopharm to fix the price at the top of the range for a deal size of HK$8.73 billion $1.13 billion, and should bode well for the multitude of other listing hopefuls currently in the market or awaiting their turn with the listing committee.

However, some observers pointed out that Sinopharm may have been a special case in that...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222